Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Xuzhou, China Clinical Trials

A listing of Xuzhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (3) clinical trials

Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy

To determine: Primary Outcome Measure: Safety (incidence of adverse events defined as dose-limited toxicity) Secondary Outcome Measures: Survival of CAR T cells in circulation measured by flow cytometry and qPCR Overall complete remission rate Tissue infiltration of transferred CAR-T cells In vitro killing potential of infiltrated CAR-T cells Phenotype of ...

Phase

0.0 miles

Learn More »

Humanized CAR-T Therapy for Treatment of B Cell Malignancy

CD19 has been extensively evaluated as a therapeutic target for recurrent or refractory B cell malignancy by chimeric antigen receptor T cell therapy, the single chain antibody sequence (scFv) against CD19 derived from a mouse hybridoma was widely employed. However, the immunogenicity of the mouse scFv sequence might be one ...

Phase

6.14 miles

Learn More »

CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

CD19 is an ideal target with great potential for treating B-cell-derived hematological malignancies. Although the complete remission rate is as high as 93% by using CD19-targeting CAR-T technology, approximately 60% patients will have recurrent disease. Among all the recurrent patients, two thirds is revealed to loss their CD19 expression on ...

Phase

6.14 miles

Learn More »